RemeGen Co., Ltd. (OTCMKTS:REGMF) Short Interest Update

RemeGen Co., Ltd. (OTCMKTS:REGMF) saw a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 340,500 shares, a decline of 70.6% from the February 13th total of 1,157,500 shares. Based on an average daily volume of 1,100 shares, the short-interest ratio is presently 309.5 days.

RemeGen Price Performance

Shares of REGMF stock opened at $1.50 on Friday. The firm’s 50-day moving average is $1.50 and its two-hundred day moving average is $1.56. RemeGen has a 12 month low of $1.50 and a 12 month high of $4.00.

RemeGen Company Profile

RemeGen Co, Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers.